upsid price
return equiti ltm
note pleas refer page end
report import disclosur
close strong note oncolog order
increas price
top line varian deliv revenu million versu estim
million consensu estim million oncolog system
revenu million versu estim million proton
solut segment also exceed expect deliv million
revenu versu estim million revenu million
versu estim million gross oncolog system order quarter
increas report constant currenc
outlook varian initi financi guidanc includ assumpt
revenu growth organ revenu growth non-gaap ep
rang vs cash flow oper
rang million non-gaap effect tax rate expect
weight averag share count
around million current model non-gaap ep
balanc sheet cash flow varian end quarter cash
equival approxim million around million debt
larg due recent activ flow oper quarter
million capit expenditur million
bottom line varian report non-gaap ep figur quarter
versu expect consensu estim strong
revenu better-than-expect gross margin primari catalyst
profit beat rel model
recommend maintain outperform invest rate
share increas price target arriv
price target attach multipl adjust ebitda estim
assum million net cash month
revenu mil estimate bold
ep estimate bold
overal varian deliv strong revenu profit perform fiscal
fourth quarter order momentum oncolog also solid varian manag
also provid initi financi guidanc somewhat better expect
term top-lin growth non-gaap ep
revenu look revenu oper segment oncolog system revenu came
million estim million revenu segment increas
versu compar period last year product revenu growth
quarter servic increas approxim
varian proton solut segment deliv million revenu declin around
versu compar quarter last year estim busi
varian revenu segment deliv million revenu versu estim
gross margin oper expens total consolid gross margin came
versu estim non-gaap gross margin
increas bp versu last year compar quarter quarter result
aid posit impact quarter tariff exclus well strong softwar
servic revenu oncolog system gener gross margin bp
yoy proton busi deliv gross margin repres
increas bp final revenu segment gener gross margin
quarter
sg expens came revenu expect non-
sg expens recent activ expens relat
astro confer impact result expens revenu
versu model
profit non-gaap ep came versu estim
consensu expect
balanc sheet cash flow varian end quarter cash equival
approxim million million debt flow oper
million quarter versu period last year
varian report strong revenu profit quarter demonstr solid
oncolog order momentum manag also provid financi guidanc
somewhat better anticip
varian financi guidanc includ expect overal revenu
growth includ organ growth non-gaap ep vs
non-gaap ep deliv non-gaap oper margin rang
oper cash flow million current model
non-gaap ep revenu growth previou non-gaap ep expect
oncolog system revenu increas around quarter solid
result includ revenu growth america region revenu growth
emea region report growth constant currenc increas
revenu asia-pacif region report well constant currenc
oncolog system order grew report dollar constant
currenc result repres nice bounc back prior quarter order
growth report slow full-year order growth
report constant currenc
america gross oncolog order million increas
europ middl east india africa region gross oncolog order increas
dollar million constant currenc final gross oncolog
order asia-pacif region million dollar
constant currenc
compani net instal base radiat therapi stand unit
result repres growth versu period last year
win quarter includ halcyon system china truebeam system
india tata trust truebeam system one edg custom
compani disclos alreadi taken order etho unit
end quarter import note compani etho system
commerci avail market small portion quarter
varian continu see strong demand softwar solut softwar
quarter uniqu softwar custom grew
approxim quarter hardwar also show strong growth
servic revenu
varian proton solut busi gener million revenu
quarter book one new order compani book four order past
six month gone year without book new proton busi
remind margin proton solut segment show uptick
quarter still well compani averag expect remain
forese futur said compani repeatedli state remain fulli
commit busi highlight effort develop potenti
revolutionari flash technolog among reason compani continu invest
area
remind varian new flash technolog shown earli pre-clin
work promis amazingli quick treatment throughput attack cancer
tumor larg spare healthi tissu trial could begin within six
month believ initi could ultim success result genuin
paradigm shift radiat therapi space
compani segment gener million quarter includ
var intervent oncolog busi consist asset relat cryoablat
embol microspher microwav ablat cardiac radioabl
varian announc current cfo gari bischop assum new role
presid var intervent oncolog solut busi begin decemb
develop lot respect mr bischop time cfo
suspect bring lot energi new role within varian michael bruff
current senior vice-president financ investor relat succeed mr bischop cfo
also like respect mr bruff quit bit believ certainli prepar
compani continu await guidanc regard plan
transit cancer care toward value-bas model expect final rule
within next two three week strongli believ varian well
posit compet space continu consid futur cancer
care may best deliv price
compani continu activ share repurchas activ
repurchas share approxim million quarter
compani still million share remain current share repurchas
author quarter end
maintain outperform invest rate share
increas price target arriv price target attach
multipl adjust ebitda estim assum million
net cash month
revenu
interest incom net
 revenu
sg revenu
pre-shar repo chg wc
million except per share data
ex pec ted outperform mark et next ont hs
sound im prov ing com pani fundament
potenti exi ts near- ter atali st
underv alu curr ent level
ex pec ted perform oughli line ark et ov er nex month
long-term potenti ex ts near -term catalyst appar
fairli alu curr ent level
ex pec ted under-perform ar ket nex onth
com pani fundam ental ay deterior ate
fulli alu over- valu cur rent level
dev elop pric tar get com pani use /e itda howev
ri ks target pric ac hiev he inc lude limit failur
 om pani eet revenu earn estim ate
follow list rate com pani cov ere ar rington earch soc iat
inc septem ber number om pani rate pe rfo rm
 epr esent com pani age li num ber com pani rate
rk et rfor epr esent com pani cover age li
num ber com pani rate pe rfor epr esent
com pani cov erag li lso eptem ber bar rington researc
sociat inc prov ide inv estm ent bank ing erv ic es within la onth
com pani utp erf orm rate com pani
ark pe rfo rm rate
 ompani
analyst certif icat ion re ear ch analyst respons prepar researc report ichael petusk cfa herebi ertifi
 iew om pani sec ur iti expr sed epor acc urat eflect per onal opinion analyst al
cer tifi part com pensat directli indir ec tli relat pecif recom endat iew contain report
researc anali st inc lude tho inv olv ed pr epar ation epor receiv direc com pen ation onnec tion wi th firm
inv estm ent bank ing activ nali st om pensat ade alar bonu base upon num erou fact inc lude
stoc price perfor manc qualiti anali inv tor client feedbac well overal pr ofit firm whic im pact
firm busi ac tiv iti inc lude ong thing institut equiti trade inv estm ent bank ing ser vice
inv tment bank serv ic es defin na rule inc lude ong thing ac ting underwrit em ber
sell gr oup ec uriti write anali st re pon ibl report michael petusk cf ember analyst
household hare omm toc om pani na sd regul adopt rule prohibit researc anali st
trade ecur iti cov er ed om pani pecifi tim period befor public ation re ear ch report
 ar rington ear ch ss ociat inc full- serv ic financ ial serv ic es firm offer wide var ieti serv ic es product client
inv tor hould ass ume arringt ear ch eek ing eek investm ent bank ing bu ine elat hip
com pani es earc overag ar rington researc receiv inv estm ent bank ing-r elat com pen ation
com pani within pa onth expect within nex thr ee month
barrington research associ inc finra-regist broker/deal clear wedbush secur fulli
disclos basi conveni client offer sever way client facilit payment
trade barrington research order may place trade desk
trader michael hutchison head trader christoph pari email address
instant messeng address brrrmh
trade broker trade may also stepped-in barrington research trade execut broker
commiss share arrang barrington commiss share agreement numer broker wall
street complet list commiss share program barrington research particip pleas contact
salesperson trade desk
follow list provid barrington research trade alloc settlement id wedbush dtc code
question trade set account relat inform pleas call trade depart
inform contain herein obtain sourc believ reliabl guarante accuraci complet
opinion estim reflect best judgment report date subject chang without notic report intend inform
purpos constitut offer solicit buy sell secur barrington research associ inc affili offic
analyst employe may time time posit secur refer herein barrington research associ inc may act
princip agent buyer seller purchas sale secur mention report barrington research associ
inc may provid may seek provid invest bank servic compani mention report report may
reproduc form without prior written consent barrington research associ inc right reserv member finra/sipc
